Peak Pharmaceutical Donates Epidemic Prevention Materials
Release time:
2023-01-12
Since the optimization and adjustment of the new crown infection epidemic management policy, there has been an explosive growth of infected people in the country, and the pressure on the supply of related materials has increased sharply. Before and after New Year's Day, the company has twice organized epidemic prevention materials, through the Jinhua City Charity Federation, Jinhua City Economic and Technological Development Zone Charity Federation targeted donations, a total value of more than 12 million yuan. 2022
12# July 30 , Shi Fu, chairman of the trade union of the group company, and Dai Jinxiao, deputy secretary of the party Committee of Jianfeng Pharmaceutical Company, donated aceclofenac sustained-release tablets 2100 boxes and disinfection alcohol 150 barrels to the municipal charity association on behalf of the pharmaceutical company. The pharmaceutical company assisted the charity association to transport these materials to 28 pension institutions in the city. 2023 1 September 2 , at the epidemic prevention and control headquarters of Jinhua economic and technological development zone, general manager Yu Jianhong and deputy general manager Huang Jinlong donated 1000 anti-epidemic material packages to Jinhua economic and technological development zone charity association on behalf of the pharmaceutical company, including aceclofenac sustained-release tablets, medical thermometers, medical masks, spray alcohol and other epidemic prevention supplies. Aceclofenac sustained-release tablets in these two donations are patented products of Spike Pharmaceuticals, which have good analgesic effects and have a significant effect on the recovery after the new coronavirus infection. The kindness of the spike has received attention and praise from all walks of life. Jiang Xiaomeng, Secretary of the Party Committee and Chairman of the Group, said in an interview with Zhejiang Radio
"Voice of Traffic" that after the "liberalization" of the epidemic prevention and control policy, the number of people infected with the society is rising, and Zhejiang will face the first wave of peak after the epidemic prevention situation turns. As "one old and one small" is a new crown susceptible group, the elderly, especially the vulnerable group prone to severe illness, the protection of elderly patients is the top priority in dealing with the peak of the first wave of the epidemic. As a leading local enterprise in Jinhua with a history of more than 28 60 29 years, Jianfeng has always received the care, help and strong support from all walks of life. Moreover, there are elderly people in the homes of its employees, "I am old and old", and they empathize with the risk of infection for the elderly. In the current special period, the peak has the responsibility to do its part in epidemic prevention in Jinhua society, to help the elderly as much as possible to protect themselves from infection, or to recover as soon as possible after infection, to successfully pass this wave of infection peak, to ease the pressure of epidemic prevention in Jinhua society and to maintain social order and stability. This is not only the consistent adherence of peak people to fulfill their social responsibilities, but also an expression of their hearts.In the three years since the outbreak of the new crown infection, the company has been upholding a high sense of social responsibility, many donations to support the anti-epidemic work, and the use of channel advantages to actively cooperate with government departments to reserve epidemic prevention materials, to ensure market supply.
It is also understood that the epidemic situation brought about by the optimization and adjustment of the epidemic prevention policy will inevitably have an impact on the business management order. In view of this situation, the company made a timely prediction of the epidemic situation, made emergency plans and arrangements in advance, and adjusted the daily epidemic prevention measures of the enterprise. In addition to doing a good job in the daily elimination of the workplace, the company implemented decentralized office work, off-peak work, off-peak production and off-peak dining, on the one hand, to reduce the infection risk of employees as much as possible, on the other hand, to ensure that infected employees have sufficient rest time and recover as soon as possible. At present, the work of the group headquarters and subordinate enterprises is stable and orderly.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page